JP7082065B2 - 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法 - Google Patents

抗Ｋｖ１．３抗体ならびにその産生方法および使用方法 Download PDF

Info

Publication number
JP7082065B2
JP7082065B2 JP2018558310A JP2018558310A JP7082065B2 JP 7082065 B2 JP7082065 B2 JP 7082065B2 JP 2018558310 A JP2018558310 A JP 2018558310A JP 2018558310 A JP2018558310 A JP 2018558310A JP 7082065 B2 JP7082065 B2 JP 7082065B2
Authority
JP
Japan
Prior art keywords
seq
sequence
region containing
limited
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018558310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521651A5 (https=
JP2019521651A (ja
Inventor
ポール コルッシ，
ジャンナ ベドネンコ，
エレナ ビシャルヤン，
アショット パポヤン，
ジョアンナ カルダレッリ，
セオドア ジー． クラーク，
アール． ダグラス カーン，
ローレ マリエン，
デル ヴォニング， バス ファン
ハールド， ハンス デ
ウィリアム ディー． ハリマン，
エレン ジェイ． コラリニ，
Original Assignee
テトラジェネティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テトラジェネティクス， インコーポレイテッド filed Critical テトラジェネティクス， インコーポレイテッド
Publication of JP2019521651A publication Critical patent/JP2019521651A/ja
Publication of JP2019521651A5 publication Critical patent/JP2019521651A5/ja
Priority to JP2021166630A priority Critical patent/JP2022002541A/ja
Application granted granted Critical
Publication of JP7082065B2 publication Critical patent/JP7082065B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018558310A 2016-05-02 2017-05-02 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法 Expired - Fee Related JP7082065B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021166630A JP2022002541A (ja) 2016-05-02 2021-10-11 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662330420P 2016-05-02 2016-05-02
US62/330,420 2016-05-02
US201662416447P 2016-11-02 2016-11-02
US62/416,447 2016-11-02
PCT/US2017/030612 WO2017192567A1 (en) 2016-05-02 2017-05-02 ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021166630A Division JP2022002541A (ja) 2016-05-02 2021-10-11 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法

Publications (3)

Publication Number Publication Date
JP2019521651A JP2019521651A (ja) 2019-08-08
JP2019521651A5 JP2019521651A5 (https=) 2020-06-18
JP7082065B2 true JP7082065B2 (ja) 2022-06-07

Family

ID=60203481

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018558310A Expired - Fee Related JP7082065B2 (ja) 2016-05-02 2017-05-02 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法
JP2021166630A Withdrawn JP2022002541A (ja) 2016-05-02 2021-10-11 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021166630A Withdrawn JP2022002541A (ja) 2016-05-02 2021-10-11 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法

Country Status (8)

Country Link
US (1) US11597763B2 (https=)
EP (1) EP3452084A4 (https=)
JP (2) JP7082065B2 (https=)
CN (1) CN109862907A (https=)
AU (1) AU2017260232B2 (https=)
CA (1) CA3022961A1 (https=)
IL (1) IL262747A (https=)
WO (1) WO2017192567A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
EP3793614A4 (en) 2018-04-30 2022-04-20 Integral Molecular, Inc. GLUCOSE TRANSPORTER-4 ANTIBODIES, PROCESSES FOR THEIR PRODUCTION AND THEIR USES
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
CA3176090A1 (en) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anti-gipr antibody and methods of use thereof
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN120865419A (zh) * 2025-08-02 2025-10-31 广东工业大学 一种用于检测肝癌标志物gpc3的禽源单链抗体、试剂盒、检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193452A1 (en) 2014-06-18 2015-12-23 Ablynx Nv Kv1.3 binding immunoglobulins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
AU2006324847A1 (en) 2005-12-15 2007-06-21 Genegrafts Ltd. Polynucleotides and polypeptide of Human KV1.3, compositions comprising same and methods of using same
WO2007139771A1 (en) 2006-05-22 2007-12-06 The Johns Hopkins University Kv channels in neurodegeneration and neuroprotection
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
JP5765814B6 (ja) 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
CN102180950B (zh) 2011-02-24 2013-06-05 华中科技大学同济医学院附属协和医院 一种人源性电压门控钾通道1.3免疫原性肽段及其用途
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
RS57422B1 (sr) 2013-01-25 2018-09-28 Janssen Biotech Inc Antagonisti kv1.3 i postupci za upotrebu
CN103713129B (zh) 2013-12-18 2016-02-10 中国医学科学院北京协和医院 分子标记物在甲状旁腺肿瘤诊断中的用途
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193452A1 (en) 2014-06-18 2015-12-23 Ablynx Nv Kv1.3 binding immunoglobulins

Also Published As

Publication number Publication date
WO2017192567A1 (en) 2017-11-09
CN109862907A (zh) 2019-06-07
EP3452084A1 (en) 2019-03-13
IL262747A (en) 2018-12-31
EP3452084A4 (en) 2020-01-01
AU2017260232A1 (en) 2018-11-29
US11597763B2 (en) 2023-03-07
AU2017260232B2 (en) 2024-07-18
CA3022961A1 (en) 2017-11-09
JP2019521651A (ja) 2019-08-08
JP2022002541A (ja) 2022-01-11
US20190144538A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
JP7082065B2 (ja) 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法
US11987627B2 (en) Anti-CD47 antibody and application thereof
AU2019394241B2 (en) CD3 antibody and pharmaceutical use thereof
AU2020352382A1 (en) Anti-human claudin 18.2 antibody and application thereof
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
US9567404B2 (en) Anti-vasa antibodies, and methods of production and use thereof
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
AU2022287551B2 (en) Mixed binding domains
WO2022267936A1 (zh) 特异性结合糖基化ceacam5的抗体
KR102800024B1 (ko) 항-ｍｙｌ9 항체
US12037409B2 (en) Antibody specifically bound to glycosylated CEACAM5
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2025086564A1 (zh) 抗人vsig4的抗体及其医药用途
WO2022100694A1 (zh) 抗体及其制备方法
WO2025228370A1 (zh) 中和呼吸道合胞病毒的抗原结合蛋白及其应用
TW202222836A (zh) 特異性結合糖基化ceacam5的抗體
CN114605546A (zh) Cd3结合分子
OA18333A (en) Anti-Vasa antibodies, and methods of production and use thereof
HK1236552A1 (en) Anti-vasa antibodies, and methods of production and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220526

R150 Certificate of patent or registration of utility model

Ref document number: 7082065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees